{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-22",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Indianapolis",
      "state": "IN",
      "country": "United States",
      "classification": "Class I",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "88764",
      "recalling_firm": "Eli Lilly & Company",
      "address_1": "839 S Delaware St",
      "address_2": "N/A",
      "postal_code": "46225-1782",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "Nationwide with the USA and Puerto Rico; Canada, Argentina, Costa Rica, Mexico",
      "recall_number": "D-0009-2022",
      "product_description": "Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe. Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285; Glucagon, NDC: 0002-8031-01",
      "product_quantity": "19,174 syringes",
      "reason_for_recall": "SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance.  There was also a lack of full drug effect upon administration.",
      "recall_initiation_date": "20210924",
      "center_classification_date": "20211014",
      "termination_date": "20240906",
      "report_date": "20211020",
      "code_info": "Lot #: D239382D, Exp. Date April 2022"
    }
  ]
}